Anti-phospholipase 2a receptor-associated membranous nephropathy in HIV-infected patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Anti-phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is extremely rare in HIV-infected patients without known co-infections and poses significant challenges in terms of management and therapeutic choice. This article presents current aspects of MN and personal experience with the treatment of MN with positive PLA2R antibodies, confirmed by kidney biopsy, in HIV-infected patients. Treatment of idiopathic membranous nephropathy with glucocorticosteroids in combination with anti-CD20+ monoclonal antibodies (rituximab) against the background of normalization of the immune status due to antiretroviral therapy has resulted in remission of nephrotic syndrome without complications associated with the use of immunosuppressive drugs. Our experience confirms the effectiveness of this therapeutic approach.

About the authors

Nadiya F. Frolova

City Clinical Hospital No. 52 of the Moscow Healthcare Department; Russian University of Medicine

Author for correspondence.
Email: nadiya.frolova@yandex.ru
ORCID iD: 0000-0002-6086-5220

Cand.Sci. (Med.), Deputy Chief Physician for Nephrology Care, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow; Moscow

Galina V. Volgina

Russian University of Medicine

Email: volginagv@mail.ru
ORCID iD: 0000-0002-7771-4074

Dr.Sci. (Med.), Professor, Department of Nephrology, N.A. Semashko Higher School of Clinical Medicine

Russian Federation, Moscow

Lyudmila Yu. Artyukhina

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: arlyu-1404@yandex.ru
ORCID iD: 0000-0003-3353-1636

Head of the Nephrology Department No.1, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow

Sergey S. Usatyuk

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: usatuk-doc@mail.ru
ORCID iD: 0000-0002-8742-3860

Head of the Nephrology Department No.2, City Clinical Hospital No.52 of the Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow

Madina M. Gadzhikulieva

Russian University of Medicine

Email: madina67@mail.ru
ORCID iD: 0000-0002-0510-5050

Dr.Sci. (Med.), Professor, Department of Infectious Diseases and Epidemiology, N.A. Semashko Higher School of Clinical Medicine

Russian Federation, Moscow

Elena V. Tsyganova

Moscow AIDS Prevention and Control Center of the Moscow Healthcare Department

Email: TsyganovaElena@yandex.ru
ORCID iD: 0000-0002-3410-2510

Cand.Sci. (Med.), Infectious Disease Specialist, Head of the Scientific and Clinical Department

Russian Federation, Moscow

Ekaterina N. Diakova

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: Katerina-diakova@mail.ru
ORCID iD: 0000-0003-1599-1639

Nephrologist, Department of Nephrology No. 2, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow

Irina L. Sysoeva

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: i.l.sysoeva@mail.ru
ORCID iD: 0000-0002-1904-9846

Nephrologist, Department of Nephrology No. 2, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow

Olga O. Chernysheva

Russian University of Medicine

Email: chernishevaoo@mail.ru
ORCID iD: 0000-0003-4712-1240

Resident Physician, Department of Infectious Diseases and Epidemiology, N.A. Semashko Higher School of Clinical Medicine

Russian Federation, Moscow

Renata A. Shakhnamasova

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: renata.sek.93@gmail.com
ORCID iD: 0009-0002-7148-7429

Nephrologist, Nephrology Department No. 2, City Clinical Hospital No. 52, Moscow Healthcare Department; Moscow City Scientific and Practical Center of Nephrology and Transplanted Kidney Pathology

Russian Federation, Moscow

References

  1. Latest global and regional statistics on the status of the AIDS epidemic. Fact sheet. UNAIDS, 2024. https://www.unaids.org/en/resources/ documents/2024/UNAIDS_FactSheet.
  2. Cervantes C.E., Atta M.G. Updates on HIV and Kidney Disease. Curr. HIV/AIDS Rep. 2023;20(2):100–10. doi: 10.1007/s11904-023-00645-1.
  3. Hou J., Nast C.C. Changing concepts of HIV infection and renal disease. Curr. Opin. Nephrol. Hypertens. 2018;27:144–52. https://doi.org/10.1097/ MNH. 0000000000000400.
  4. Волгина Г.В., Томилина Н.А., Гаджикулиева М.М. Современная концепция хронической болезни почек при ВИЧ-инфекции. Нефрология и диализ. Приложение к 2021;23(1):11–31. doi: 10.28996/2618-9801-2021-1suppl-11-31. [Volgina G.V., Tomilina N.A., Gadzhikulieva M.M. Modern concept of chronic kidney disease in HIV patients. Nephrol. Dialys. 2021;Suppl. to 23(1):11–31]. doi: 10.28996/2618-9801-2021-1suppl-11-31.
  5. Kudose S., Santoriello D., Bomback A.S. et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 2020;97(5):1006–16. doi: 10.1016/j.kint.2020.01.018.
  6. Wearne N., Davidson B. HIV-associated kidney disease: the changing spectrum and treatment priorities. Curr. Opin. Nephrol. Hypertens. 2024;33(6):603–12. doi: 10.1097/MNH.0000000000001018.
  7. Гаджикулиева М.М., Ющук Н.Д., Волгина Г.В. и др. Распространенность и клинико-морфологическая характеристика поражений почек при ВИЧ-инфекции. Нефрология и диализ. 2012;14(1):31–40. [Gadzhikulieva M.M., Yushchuk N.D., Volgina G.V., et al. Rasprostranennost' i kliniko-morfologicheskaya kharakteristika porazhenii pochek pri VICH-infektsii. Nefrol. Dial. 2012;14(1):31–40 (In Russ.)].
  8. Lucas А., Wyatt С.М. HIV at 40: kidney disease in HIV treatment, prevention, and cure. Kidney Int. 2022t;102(4):740–9. doi: 10.1016/j.kint.2022.06.021.
  9. Swanepoel C.R., Atta M.G., D'Agati V.D. et al. Conference Participants. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;93:545–59. https://doi.org/10.1016/j.kint.2017.11.007.
  10. Ющук Н.Д., Гаджикулиева М.М., Волгина Г.В. и др. Иммунокомплексное поражение почек при ВИЧ-инфекции. Инфекционные болезни: новости, мнения, обучение. 2020;9(2):57–62. [Yushchuk N.D., Gadzhikulieva M.M., Volgina G.V. et al. HIV-associated immune complex kidney disease. Infektsionnye bolezni: novosti, mneniya, obuchenie. Inf. Dis. News Opin. Train. 2020;9(2):57–62]. (In Russ.)]. doi: 10.33029/2305-3496-2020-9-2-57-62.
  11. Волгина Г.В., Томилина Н.А., Гаджикулиева М.М., Фролова Н.Ф. Гломерулярные болезни почек при ВИЧ-инфекции: Современные представления об этиологии, классификации, патогенезе. Нефрология и диализ. 2021;23(1):42–61. [Volgina G.V., Tomilina N.A., Gadzhikulieva M.M., Frolova N.F. Glomerular kidney diseases in HIV-infection: Modern views on etiology, classification, pathogenesis. Nephrol. Dial. 2021;Suppl.23(1):42–61]. doi: 10.28996/2618-9801-2021-1suppl-42-61.
  12. Kofotolios I., Tsiakas S., Skalioti C. et al. Treatment of HIV-Associated Lupus-like Membranous Nephropathy with Tacrolimus: A Case Report and Review of the Literature. Life (Basel). 2023;13(3):641. doi: 10.3390/life13030641.
  13. Efe O., So P.N.H., Anandh U. et al. An Updated Review of Membranous Nephropathy. Indian J. Nephrol. 2024;34(2):105–18. doi: 10.25259/ijn_317_23. [Epub 2024 Apr 10].
  14. Beck L.H., Bonegio R.G.B., Lambeau G. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009;361:11–21. https://doi.org/10.1056/NEJMoa0810457.
  15. Zhang C., Zhang M., Chen D., et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. J. Clin. Pathol. 2019;72(10):705–11. doi: 10.1136/jclinpath-2019-205852.
  16. Allinovi M., Lugli G., Rossi F. et al. Accuracy of serum Pla2r antibody detected by indirect immunofluorescence in diagnosing biopsy-proven primary membranous nephropathy: a single-center experience and a systematic review of the literature. J. Nephrol. 2023;36(2):281–3. Doi: 10.1007/ s40620-022-01528-1.
  17. Sethi S. New antigens in Membranous Nephropathy. JASN. 2021;32:268–78. doi: 10.1681/ASN.2020071082.
  18. Ponticelli C., Glassock R.J. Glomerular diseases: membranous nephropathy – modern view. Clin. J. Am. Soc. Nephrol. 2014;9(3):609–16. doi: 10.2215/CJN.04160413.
  19. Dahan K., Gillion V., Johanet C. et al. The Role of PLA2R antibody in treatment of membranous nephropathy. Kidney Int. Rep. 2018;3:498–501. doi: 10.1016/j.ekir.2017.10.013.
  20. van de Logt A.E., Fresquet M., Wetzels J.F., Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96:1292–302. doi: 10.1016/j.kint.2019.07.014.
  21. Gu Y., Xu H., Tang D. Mechanisms of Primary Membranous Nephropathy. Biomolecules. 2021;11(4):513. doi: 10.3390/biom11040513.
  22. De Vriese A.S. et al. A proposal for a serology-based approach to membranous nephropathy. J. Am. Soc. Nephrol. 2017;28(2):421–30. https://doi.org/10.1681/ASN.2016070776.
  23. Nikolopoulou A., Teixeira C., Cook H.T. et al. Membranous nephropathy associated with viral infection. Clin. Kidney J. 2021;14:876–83. doi: 10.1093/ckj/sfaa026.
  24. Lönnbro-Widgren J., Ebefors K., Mölne J. et al. Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin. Kidney J. 2015;8:433–9. doi: 10.1093/ckj/sfv049.
  25. Kaur Р., Prabhahar А., Niranjan А. et al. Viral Infection Associated Membranous Nephropathy: Clinical Presentation and Outcomes. Indian J Nephrol. 2025;35(1):70–6. doi: 10.25259/IJN_57_2024.
  26. Charu V., Andeen N., Walavalkar V. et al. Membranous nephropathy in patients with HIV: a report of 11 cases. BMC. Nephrol. 2020;21:401. https://doi.org/10.1186/s12882-020-02042-x.
  27. Ma J., Zheng Q., Zhang H. et al. The spectrum of kidney biopsy findings in Chinese HIV-infected patients. HIV. Med. 2022;23(Suppl. 1):23–31. doi: 10.1111/hiv.13246.
  28. Chen R., Wang J., Xie Q. et al. Favorable outcome in PLA2R positive HBV-associated membranous nephropathy. BMC. Nephrol. 2022;23:246. doi: 10.1186/s12882-022-02871-y.
  29. Baker L.W., Jimenez-Lopez J., Geiger X.J., Aslam N. Malignancy-associated membranous nephropathy with positive anti-PLA2R autoantibodies: Coincidence or connection. Case Rep. Nephrol. Dial. 2021;11:334–9. doi: 10.1159/000520399.
  30. Wang J.L., Sun Y.L., Kang Z., et al. Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report. World J. Clin. Cases. 2023;11(22):5309–15. doi: 10.12998/wjcc.v11.i22.5309.
  31. Smatti M.K., Cyprian F.S., Nasrallah G.K. et al. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019;11. [PMID: 31430946]. doi: 10.3390/v11080762.
  32. Fervenza F.C., Appel G.B., Barbour S.J. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 2019;381:36–46. doi: 10.1056/NEJMoa1814427.
  33. Heerspink H.J., Stefánsson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383:1436–46. doi: 10.1056/NEJMoa2024816.
  34. Herrington W.G., Staplin N., Wanner C. et al.; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2023;388:117–27. doi: 10.1056/NEJMoa2204233.
  35. Hønge B.L., Petersen M.S, Jespersen S. et al. Bissau HIV Cohort study group. T-cell and B-cell perturbations are similar in ART-naive HIV-1 and HIV-1/2 dually infected patients. AIDS. 20191;33(7):1143–53. doi: 10.1097/QAD.0000000000002185.
  36. de Carvalho P.S., Leal F.E., Soares M.A. Clinical and Molecular Properties of Human Immunodeficiency Virus-Related Diffuse Large B-Cell Lymphoma. Front. Oncol. 20219 11:675353. doi: 10.3389/fonc.2021.675353.
  37. Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385–94. doi: 10.1182/blood-2018-01-791400.
  38. Prudhvi K., Schwartz D., Fisher M. Rituximab for Lupus-Like Membranous Nephropathy in the Setting of Well-Controlled HIV Infection. Am. J. Ther. 2020;28(6):e732-e734. doi: 10.1097/MJT.0000000000001220.
  39. Teisseyre M., Cremoni M., Boyer-Suavet S. et al. Rituximab immunomonitoring predicts remission in membranous nephropathy. Front. Immunol. 2021;12:738788. https://doi.org/10.3389/fimmu.2021.738788.
  40. Seitz-Polski B., Dahan K., Debiec H., et al. High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2019;14:1173–82. https://doi.org/10.2215/CJN.11791018.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Bionika Media